Market closedNon-fractional
Tarsus Pharmaceuticals/TARS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Ticker
TARS
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Irvine, United States
Employees
244
Website
www.tarsusrx.com
TARS Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$4.70
EPS
1.11
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
1.11
Financial strength
Current ratio
8.012
Quick ratio
7.757
Long term debt to equity
11.46
Total debt to equity
11.46
Interest coverage (TTM)
-42.77%
Management effectiveness
Return on assets (TTM)
-34.77%
Return on equity (TTM)
-66.07%
Valuation
Price to revenue (TTM)
20.916
Price to book
3.85
Price to tangible book (TTM)
3.9
Price to free cash flow (TTM)
-6.421
Growth
Revenue change (TTM)
53.22%
Earnings per share change (TTM)
88.03%
3-year revenue growth (CAGR)
8.38%
3-year earnings per share growth (CAGR)
50.81%
What the Analysts think about TARS
Analyst Ratings
Majority rating from 9 analysts.
TARS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$28M
112.31%
Net income
-$36M
-14.80%
Profit margin
-129.34%
-59.87%
TARS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.17
-$1.28
-$1.31
-$1.01
-
Expected
-$1.08
-$1.37
-$1.36
-$1.20
-$0.93
Surprise
8.48%
-6.26%
-3.86%
-16.17%
-
TARS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tarsus Pharmaceuticals stock?
Tarsus Pharmaceuticals (TARS) has a market cap of $1.1B as of July 27, 2024.
What is the P/E ratio for Tarsus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of July 27, 2024.
Does Tarsus Pharmaceuticals stock pay dividends?
No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Tarsus Pharmaceuticals dividend payment date?
Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.
What is the beta indicator for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Tarsus Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.